Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.44 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16351201 | 0.96 | GRB2 (0.47) | GRB2CAPN1SLC6A2NTSR1NTSR2 | |
| SCHEMBL16351063 | 0.93 | GRB2 (0.47) | GRB2CAPN1SLC6A2NTSR1NTSR2 | |
| SCHEMBL12237948 | 0.87 | CXCR4 (0.49) | GRB2CAPN1 | |
| SCHEMBL16340685 | 0.81 | GRB2 (0.49) | GRB2CAPN1SLC6A2NTSR1NTSR2 | |
| SCHEMBL29506907 | 0.81 | SLC6A2 (0.53) | SLC6A2NTSR1NTSR2NMUR2NMUR1 | |
| SCHEMBL24485881 | 0.79 | MAPK8 (0.46) | — | |
| SCHEMBL29629087 | 0.79 | MAPK8 (0.46) | — | |
| SCHEMBL31049828 | 0.79 | F2 (0.41) | GRB2CAPN1CTSBNMUR2NMUR1 | |
| SCHEMBL31542148 | 0.79 | NTSR2 (0.52) | CAPN1SLC6A2NTSR1NTSR2CTSB | |
| SCHEMBL31542147 | 0.78 | NTSR2 (0.51) | CAPN1SLC6A2NTSR1NTSR2CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | GRB2 756/4885CAPN1 1439/4885SLC6A2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.